Dunn Edmund
Principal Accounting Officer
Dunn Edmund has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Mar 5, 2026.
On the most recent filing, Dunn Edmund is listed as Principal Accounting Officer at Monte Rosa Therapeutics, Inc. Inside the rolling window, Dunn Edmund reported no open-market purchases and 4 open-market sales totaling $483K in GLUE. The largest disclosed transaction in the window is a sale of 25,164 GLUE shares on Feb 27, 2026, worth $456K.
Companies traded
Other insiders at GLUE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$483K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Dunn Edmund made?
Dunn Edmund has filed 3 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does Dunn Edmund trade?
Dunn Edmund has filed SEC Form 4 disclosures for 1 company, including GLUE.
When was Dunn Edmund's most recent SEC Form 4 filing?
Dunn Edmund's most recent SEC Form 4 filing on Tracefour is dated Mar 5, 2026.
What is Dunn Edmund's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Dunn Edmund is listed as Principal Accounting Officer.
What is Dunn Edmund's total buy and sell value in the current window?
Inside the rolling retention window, Dunn Edmund bought $0 and sold $483K based on SEC Form 4 filings.
What was Dunn Edmund's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 25,164 GLUE shares on 2026-02-27, worth $456K, per SEC Form 4 filings.